Benefits for Biotechs: • US-regulated jurisdiction compliant with FDA • Early commercialization and outcome data Benefits for Patients: • Flexible and fast access post-phase-1
Eligible Treatments
Post-Phase 1 therapies and select pre-Phase 1 programs with supporting data get access.
Real-World Evidence
Generate treatment experience and patient data outside traditional trial pathways.
Commercial Opportunity
Generate revenue through structured treatment deployment and licensing arrangements.
Public voices highlighting the importance and potential of Montana Senate Bill 535.
Infinita works across the operational layers required to move therapies from eligibility assessment to real-world deployment.
Infinita Coordinates Emerging Paths for Biotech Deployment.
Our role is not to develop therapies or approve treatments, but to help coordinate the systems, stakeholders, and processes that make deployment possible.
Emerging Pathway Expertise
Deep familiarity with emerging treatment access frameworks and the requirements needed to navigate them.
Operational Coordination
Experience coordinating across review, licensing, clinical, and deployment stakeholders within a single process.
Integrated Infrastructure
Access to a growing network of partners involved in treatment review, licensing, and delivery.
Execution Focus
A practical approach centered on real-world deployment, evidence generation, and operational outcomes.
Treatment Review.
Apply to be eligibile for clinical use under Montana right to try
